Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$6.78 -1.0%	$6.23	$3.56 ▼ $12.92	$382.66M	0.48	360,393 shs	232,942 shs
FULC Fulcrum Therapeutics	$6.64 -2.6%	$7.13	$2.32 ▼ $9.90	$359.16M	2.47	588,321 shs	475,521 shs
NBTX Nanobiotix	$8.80 +11.3%	$5.70	$2.76 ▼ $8.96	$421.87M	0.45	11,310 shs	13,564 shs
OCX OncoCyte	$3.18 +16.3%	$3.07	$1.92 ▼ $4.75	$90.80M	0.97	58,260 shs	100,514 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	+9.08%	+14.74%	+60.80%	-38.73%
FULC Fulcrum Therapeutics	0.00%	+5.08%	-10.85%	-1.59%	-26.19%
NBTX Nanobiotix	0.00%	+7.18%	+50.38%	+100.76%	+59.80%
OCX OncoCyte	0.00%	0.00%	0.00%	+13.39%	+4.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.6927 of 5 stars	3.6	3.0	3.3	1.7	0.0
FULC Fulcrum Therapeutics	1.3605 of 5 stars	3.3	1.0	1.3	1.7	0.0
NBTX Nanobiotix	0.8208 of 5 stars	1.3	3.0	3.3	0.0	0.6
OCX OncoCyte	1.4432 of 5 stars	3.4	0.0	0.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.14	Buy	$29.00	327.73% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	14.03% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	-9.09% Downside
OCX OncoCyte	2.75	Moderate Buy	$6.06	90.94% Upside

Current Analyst Ratings Breakdown

Latest OCX, ATXS, NBTX, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ATXS Astria Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ATXS Astria Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $26.00
8/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/21/2025	OCX OncoCyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/21/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $8.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.97 per share	N/A
FULC Fulcrum Therapeutics	$80M	4.49	N/A	N/A	$4.51 per share	1.47
NBTX Nanobiotix	$39.18M	10.77	N/A	N/A	($1.51) per share	-5.83
OCX OncoCyte	$3.84M	23.63	N/A	N/A	($0.70) per share	-4.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$2.01	N/A	N/A	N/A	N/A	-56.39%	-36.08%	N/A
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
OCX OncoCyte	-$60.66M	-$3.53	N/A	N/A	N/A	-1,516.06%	-215.59%	-27.23%	N/A

Latest OCX, ATXS, NBTX, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	-$0.57	+$0.04	-$0.57	$16.00 million	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	14.89	14.89
FULC Fulcrum Therapeutics	N/A	24.42	24.42
NBTX Nanobiotix	N/A	1.04	1.04
OCX OncoCyte	0.20	3.74	3.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
FULC Fulcrum Therapeutics	89.83%
NBTX Nanobiotix	38.81%
OCX OncoCyte	55.35%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
FULC Fulcrum Therapeutics	7.00%
NBTX Nanobiotix	3.45%
OCX OncoCyte	2.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.44 million	53.90 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
NBTX Nanobiotix	100	47.94 million	46.29 million	Not Optionable
OCX OncoCyte	120	28.60 million	28.01 million	No Data

OCX, ATXS, NBTX, and FULC Headlines

Recent News About These Companies

Oncocyte Exits Irvine, Rebrands as Insight Molecular Diagnostics

June 18, 2025 | ocbj.comO

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

June 17, 2025 | globenewswire.com

Oncocyte Corp. Adjusts Pricing for GraftAssureCore™ Assay to $2,753, Enhancing Market Opportunities and Reimbursement Potential

May 21, 2025 | nasdaq.com

Oncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 20, 2025 | finanznachrichten.de

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

May 19, 2025 | finance.yahoo.com

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025 | globenewswire.com

Oncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business Progress

May 13, 2025 | finanznachrichten.de

OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative

May 13, 2025 | msn.com

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025 | globenewswire.com

OncoCyte Q1 2025 Earnings Preview

May 11, 2025 | msn.com

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025 | globenewswire.com

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025 | prismmediawire.comP

Why OncoCyte Corporation’s (OCX) Stock Is Up 5.11%

May 7, 2025 | aaii.comA

Best Momentum Stocks to Buy for May 6th

May 6, 2025 | zacks.com

New Strong Buy Stocks for May 6th

May 6, 2025 | zacks.com

Oncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial Progress

April 30, 2025 | finanznachrichten.de

Oncocyte study links blood test to kidney rejection markers

April 30, 2025 | investing.com

Oncocyte Provides Positive Update on Clinical Trial Progress

April 30, 2025 | globenewswire.com

Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity

April 29, 2025 | taiwannews.com.twT

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCX, ATXS, NBTX, and FULC Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$6.78 -0.07 (-1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$6.78 0.00 (-0.07%)

As of 04:10 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$6.64 -0.18 (-2.64%)

Closing price 04:00 PM Eastern

Extended Trading

$6.64 +0.00 (+0.08%)

As of 04:46 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Nanobiotix NASDAQ:NBTX

$8.80 +0.89 (+11.25%)

Closing price 03:59 PM Eastern

Extended Trading

$8.75 -0.05 (-0.57%)

As of 04:15 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

OncoCyte NASDAQ:OCX

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time